RxDoctor Payments Data

Jordan Holder

Family · Rainbow City, ALNPI 1124529789

Payments from drug & device makers

$2,226in general payments, 2019–2025

Across 83 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galt Pharmaceuticals, LLC$897
  • AbbVie$663
  • Lilly USA, LLC$208
  • Novo Nordisk$139
  • AstraZeneca$130
  • Bayer$48
  • plus $141 from 5 others

What the payments were for

  • Food & beverage$2,226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Galt Pharmaceuticals, LLC1$897
AbbVie44$663
Lilly USA, LLC11$208
Novo Nordisk8$139
AstraZeneca7$130
Bayer3$48
Pfizer3$48
Amgen3$47
Boehringer Ingelheim1$17
Amarin Pharma, Inc.1$16
Exact Sciences1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,226 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$52,509
Medicare patients
129
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$67,128
MounjaroTirzepatide34$42,534
FarxigaDapagliflozin Propanediol29$34,247
JardianceEmpagliflozin15$25,110
EliquisApixaban19$21,373
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,681
Xigduo XrDapaglifloz Propaned/Metformin21$17,302
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,692
Repatha SureclickEvolocumab11$10,470
VascepaIcosapent Ethyl18$10,062
JanumetSitagliptin Phos/Metformin Hcl11$6,627
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$4,402
Ezetimibe62$3,757
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$3,372
Rosuvastatin Calcium131$3,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$139$67,12840 claims
AstraZenecaFarxiga, Breztri Aerosphere$130$44,93944 claims
Lilly USA, LLCMounjaro$208$42,53434 claims
Boehringer IngelheimJardiance$17$25,11015 claims
PfizerEliquis$48$21,37319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Rainbow City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →